loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
Client Virtual Booth
Menu
Country
Country

China

Address
Address

Rooms 601-606, Building 2, Hi-tech Incubator Building, High-tech No. 1 Roa...

Telephone
Telephone

+86-0755-26957330

LinkedIn
LinkedIn

Twitter
Twitter

Additional Info
Additional Info
Shenzhen Chipscreen Pharmaceutical Ltd. Company address: 21 Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen Tel: +86-0755-84533320 Fax: +86-0755-84533306 Chengdu Chipscreen Pharmaceutical Ltd. Address of Chengdu operation: A701, Maoye Center, 28 Tianfu Avenue North Section, Hi-tech Zone, Chengdu Address of Chengdu base: No. 298, Kangqiang No.1 Road, High tech West District, Chengdu Landline: +86-028-85353615 Fax: +86-028-85353615 Beijing Clinical Research Center Company address: 0311,3rd floor, Ruichen International Center, No. 13 South Nongzhuanguan Road, Chaoyang District, Beijing Tel: +86-010-59458810 Shanghai Business Unit On Oncology Company address: 2506-2507, Yuanda Building, 360 Changshou Road, Putuo District, Shanghai Tel: +86-021-61407279
Country
China
LinkedIn
Telephone
+86-0755-26957330
Address
Rooms 601-606, Building 2, Hi-tech Incubator Building, High-tech No. 1 Road, Nanshan District Science Park, Shenzhen
Others
Shenzhen Chipscreen Pharmaceutical Ltd.
Company address: 21 Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen Tel: +86-0755-84533320 Fax: +86-0755-84533306
Chengdu Chipscreen Pharmaceutical Ltd.
Address of Chengdu operation: A701, Maoye Center, 28 Tianfu Avenue North Section, Hi-tech Zone, Chengdu Address of Chengdu base: No. 298, Kangqiang No.1 Road, High tech West District, Chengdu
Landline: +86-028-85353615
Fax: +86-028-85353615
Beijing Clinical Research Center
Company address: 0311,3rd floor, Ruichen International Center, No. 13 South Nongzhuanguan Road, Chaoyang District, Beijing Tel: +86-010-59458810
Shanghai Business Unit On Oncology
Company address: 2506-2507, Yuanda Building, 360 Changshou Road, Putuo District, Shanghai Tel: +86-021-61407279
Post Enquiry
POST ENQUIRY